Online ISSN: 3007-0244,
Print ISSN:  2410-4280
Relevance: In January 2020, the World Health Organization (WHO) announced the spread of a new coronavirus infection, COVID-19. The clinical picture of COVID-19 is wide, ranging from asymptomatic infection to acute respiratory distress syndrome, most often ending in death. Some viral infections are known to be followed by lifelong immunity, while others can lead to repeated infections throughout life. There is an urgent need to better understand whether those who have had COVID-19 are protected from reinfection or not. The aim. In the present study, we examined the association of IL2, IL6, and IL10 gene polymorphisms with COVID-19 reinfection and its severity in two cases of the disease. Materials and methods: A total of 301 patients with a confirmed diagnosis of COVID-19 took part in a retrospective study, of which 76 patients had a second illness. Genetic research was carried out by real-time PCR. Results: Of the 22 initially severe patients, 7 had re-developed COVID-19 in a severe form and 15 in a mild form. Of the 54 patients who first became ill with COVID-19 in a mild form, 16 re-developed a severe form of the disease and 38 re-developed a mild form. Results of the multifactorial inheritance model of IL2 rs1801274, IL6 rs2069840, IL10 rs1800872 gene polymorphisms showed no statistically significant association with recurrent COVID-19 disease episode (p>0.2). Conclusion. Polymorphisms of cytokine genes IL2, IL6, IL10 are not associated with the severity of COVID-19 reinfection. Our results once again confirm the lack of long-term immunity after COVID-19 infection and the risk of reinfection, regardless of the severity of the first episode.
Assiya А. Yessenbayeva1*, Meruyert R. Massabayeva1, Bakytbek A. Apsalikov1, Zaure S. Zholambayeva1, Meruyert O. Khamitova2, Zaituna G. Khamidullina2, Laura T. Kassym2 1 NCJSC “Semey Medical University”, Semey, Republic of Kazakhstan; 2 NCJSC “Astana Medical University”, Astana, Republic of Kazakhstan.
1. Abu‐Raddad L.J., Chemaitelly H., Malek J.A. et al. Assessment of the risk of SARS‐CoV‐2 re‐infection in an intense re‐exposure setting // Clin Infect Dis. 2020. ciaa1846. 10.1093/cid/ciaa1846 2. Amanna I.J., Carlson N.E., Slifka M.K. Duration of humoral immunity to common viral and vaccine antigens // N Engl J Med 2007. 357:1903–15. 3. Arafkas M., Khosrawipour T., Kocbach P. et al. Current meta‐analysis does not support the possibility of COVID‐19 re‐infections // J Med Virol. 2021. 93(3):1599‐1604. 4. Atalla E., Kalligeros M., Giampaolo G., Mylona E.K., Shehadeh F., Mylonakis E. Readmissions among patients with COVID‐19 // Int J Clin Pract. 2021. 75(3):e13700. 5. Azam M., Sulistiana R., Ratnawati M. et al. Recurrent SARS‐CoV‐2 RNA positivity after COVID‐19: a systematic review and meta‐analysi // Sci Rep. 2020. 10(1):20692. 6. Breathnach A.S., Riley P.A., et al. Prior COVID‐19 significantly reduces the risk of subsequent infection, but re‐infections are seen after eight months // J Infect. 2021. 82(4):e11‐e12. 10.1016/j.jinf.2021.01.005. 7. Brouqui P., Colson P., Melenotte C. et al. COVID-19 re-infectio // Eur J Clin Invest. 2021 May. 51(5):e13537. doi: 10.1111/eci.13537. 8. Caralis P. Case Reports of COVID 19 Recurrence // J Prim Care Community Health. 2021. 12:2150132720982752. 9. Chakravarty D., Nair S.S., Hammouda N. et al. Sex differences in SARS‐CoV‐2 infection rates and the potential link to prostate cancer // Commun Biol. 2020. 3(1):1‐2. 10. Chen G., Wu D., Guo W. et al. Clinical and immunological features of severe and moderate coronavirus disease 2019 // J Clin Invest. 2020;130(5):2620‐2629 11. Chen N., Zhou M., Dong X., Qu J. et al. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: A descriptive study // Lancet, 395(10223), 507–513. 10.1016/S0140-6736(20)30211-7 12. Cohen J.I., Burbelo P.D. Reinfection With SARS-CoV-2: Implications for Vaccines // Clin Infect Dis. 2021 Dec 6;73(11):e4223-e4228. doi: 10.1093/cid/ciaa1866. 13. Couch R.B., Kasel J.A. Immunity to influenza in man // Annu Rev Microbiol. 1983. 37(1):529‐549. 14. Fajgenbaum D.C., June C.H. Cytokine Storm // N Engl J Med. 2020 Dec 3;383(23):2255-2273. doi: 10.1056/NEJMra2026131. 15. Felix H.C., Seaberg B., Bursac Z., Thostenson J., Stewart M.K. Why do patients keep coming back? Results of a re‐admitted patient survey // Soc Work Health Care. 2015. 54(1):1‐15. 16. Feng Y., Ling Y., Bai С. et al. COVID‐19 with different severities: A multicenter study of clinical features // American Journal of Respiratory and Critical Care Medicine, 2020. 201(11), 1380–1388. 10.1164/rccm.202002-0445OC 17. Gudbjartsson D.F., Helgason A., Jonsson H. et al. Spread of SARS‐CoV‐2 in the Icelandic Population // N Engl J Med. 2020. 382(24):2302‐2315. 18. Hall V.J., Foulkes S., Charlett A. et al. SARS‐CoV‐2 infection rates of antibody‐positive compared with antibody‐negative health‐care workers in England: a large, multicentre, prospective cohort study (SIREN) // Lancet. 2021. 397(10283):1459‐1469. 19. Hu B., Huang S., Yin L. The cytokine storm and COVID-19 // J Med Virol. 2021 Jan. 93(1):250-256. doi: 10.1002/jmv.26232. 20. Huang C., Wang Y., Li X. et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China // Lancet 2020;395:497-506. 21. Hunter C.A., Jones S.A. IL-6 as a keystone cytokine in health and disease // Nat Immunol. 2015. 16(5):448–457. doi: 10.1038/ni.3153. 22. Kang H., Wang Y., Tong Z., Liu X. Retest positive for SARS-CoV-2 RNA of "recovered" patients with COVID-19: Persistence, sampling issues, or re-infection? // J Med Virol. 2020 Nov. 92(11):2263-2265. doi: 10.1002/jmv.26114. 23. Lemoine M., Chevaliez S., Bastard JP. et al. Association between IL28B polymorphism, TNFα and biomarkers of insulin resistance in chronic hepatitis C‐related insulin resistance // Journal of viral hepatitis. 2015. Vol.22, №11. Р.890-896. 24. Liu J., Li S., Liu J. et al. Longitudinal characteristics of lymphocyte responses and cytokine profiles in the peripheral blood of SARS‐CoV‐2 infected patients // EBioMedicine. 2020. 55:102763. 25. Niederman M.S., Richeldi L., Chotirmall S.H., Bai C. Rising to the challenge of COVID‐19: Advice for pulmonary and critical care and an agenda for research // American Journal of Respiratory and Critical Care Medicine, 2020. 201(9), 1019–1022. 10.1164/rccm.202003-0741ED. 26. Pilz S., Chakeri A., Ioannidis J.P. et al. SARS‐CoV‐2 re‐infection risk in Austria // Eur J Clin Invest. 2021. 51(4):e13520. 27. Slifka M.K., Ahmed R. Long-term humoral immunity against viruses: revisiting the issue of plasma cell longevity // Trends Microbiol. 1996. 4:394–400. 28. Sotoodeh Ghorbani S., Taherpour N. et al. Epidemiologic characteristics of cases with reinfection, recurrence, and hospital readmission due to COVID-19: A systematic review and meta-analysis // J Med Virol. 2022 Jan. 94(1):44-53. doi: 10.1002/jmv.27281. 29. Тanaka T., Narazaki M., Kishimoto T. IL-6 in inflammation, immunity, and disease // Cold Spring Harb Perspect Biol. 2014. 4doi: 10.1101/cshperspect.a016295. 6(10):a016295. 30. Tian X., Li C., Huang A. et al. Potent binding of 2019 novel coronavirus spike protein by a SARS coronavirus‐specific human monoclonal antibody // Emerg Microbes Infect. 2020. 9:382‐385. 31. To K.K., Tsang O.T., Leung W.S. et al. Temporal profiles of viral load in posterior oropharyngeal saliva samples and serum antibody responses during infection by SARS‐CoV‐2: an observational cohort study // Lancet Infect Dis. 2020. 20:565‐574. 32. Wajnberg A. et al. Robust neutralizing antibodies to SARS‐CoV‐2 infection persist for months // Science. 2020. 370(6521):1227‐1230. 10.1126/science.abd7728. 33. Wu C., Chen X., Cai С. et al. Risk factors associated with acute respiratory distress syndrome and death in patients with coronavirus disease 2019 pneumonia in Wuhan, China // JAMA Intern Med, 2020. 180, 934. 10.1001/jamainternmed.2020.0994. 34. Wu F., Wang A., Liu M. et al. Neutralizing antibody responses to SARS‐CoV‐2 in a COVID‐19 recovered patient cohort and their implications // medRxiv. 2020. 2020.2003.2030.20047365. 35. Yildirim Z., Sahin O.S., Yazar S., Bozok Cetintas V. Genetic and epigenetic factors associated with increased severity of Covid-19 // Cell Biol Int. 2021 Jun. 45(6):1158-1174. doi: 10.1002/cbin.11572. 36. Zhang W. et al. The use of anti-inflammatory drugs in the treatment of people with severe coronavirus disease 2019 (COVID-19): the experience of clinical immunologists from China // Clin Immunol: 2020. 108393. 37. Zhao J. et al. Antibody responses to SARS‐CoV‐2 in patients of novel coronavirus disease 2019 // Clin Infect Dis. 2020. 19. 71(16):2027-2034. doi: 10.1093/cid/ciaa344. 38. Zhe Xu., Lei Shi., Yijin Wang, Jiyuan Zhang, Lei Huang et al. Pathological findings of COVID-19 associated with acute respiratory distress syndrome // Lancet.Respir Med. 2020. 8:420–2. 10.1016/S2213-2600(20)30076-X. 39. Zhu Z., Cai T. et al. Clinical value of immune-inflammatory parameters to assess the severity of coronavirus disease 2019 // Int J Infect Dis 2020. 95:332-339.
Количество просмотров: 303

Ключевые слова:

Категория статей: COVID-19 - Актуальная тема

Библиографическая ссылка

Yessenbayeva A.А., Massabayeva M.R., Apsalikov B.A., Zholambayeva Z.S., Khamitova M.O., Khamidullina Z.G., Kassym L.T. Effect of genetics polymorphisms on reinfection with COVID-19 and progression severity // Nauka i Zdravookhranenie [Science & Healthcare]. 2023, (Vol.25) 3, pp. 16-21. doi 10.34689/SH.2023.25.3.002

Авторизируйтесь для отправки комментариев